Neuroblastoma: The impact of biology and cooperation leading to personalized treatments
Neuroblastoma: The impact of biology and cooperation leading to personalized treatments
复制标题
神经母细胞瘤：生物学和合作的影响导致个性化治疗
DOI：
10.3109/10408363.2012.683483
复制
发表时间：
2012
影响因子：
10
通讯作者：
M. Irwin
中科院分区：
文献类型：
--
作者：
C. Owens;M. Irwin
神经母细胞瘤是儿童最常见的颅外实体瘤。它是一种异质性疾病，由神经脊源性肿瘤组成，具有显著不同的临床行为。它可以以各种各样的方式出现，包括有可能自发消退的病变，或者作为一种对所有形式的现代治疗都具有抵抗力的极具侵袭性的转移性癌症。它们可以出现在交感神经系统的任何地方。发病年龄的中位数约为18个月。尿儿茶酚胺(HVA和VMA)是高度敏感和特异的肿瘤标志物，用于诊断、治疗反应评估和治疗后监测。来自北美、欧洲和日本的最大的国家治疗小组已经成立了国际神经母细胞瘤风险小组特别工作组(INRG)，以确定预后因素，了解这种罕见疾病的肿瘤发生机制，并开发多种治疗方法，以改善结果和减少与治疗相关的毒性。这一国际合作使我们对神经母细胞瘤分子发病机制的认识有了很大的飞跃。如果病变是可切除的，则分期较低的疾病可以治愈。不能切除的疾病(局部和转移性)的治疗根据临床特征(发病年龄、分期调查)和特定的肿瘤生物标志物(包括组织病理学分析、染色体异常和癌基因表达的量化(MYCN))而分层。高危神经母细胞瘤的现代治疗是儿科肿瘤学治疗发展的典范。通过多种方式的治疗，包括化疗、手术、放射治疗、干细胞移植的清髓治疗、免疫治疗和分化治疗，结果有了很大的改善；这些都构成了全世界的护理标准。此外，较新的靶向疗法正在进行I/II期试验。如果成功，这些药物将被纳入主流治疗计划。
Neuroblastoma is the most common extra-cranial solid tumor in children. It is a heterogeneous disease, consisting of neural crest-derived tumors with remarkably different clinical behaviors. It can present in a wide variety of ways, including lesions which have the potential to spontaneously regress, or as an extremely aggressive form of metastatic cancer which is resistant to all forms of modern therapy. They can arise anywhere along the sympathetic nervous system. The median age of presentation is approximately 18 months of age. Urinary catecholamines (HVA and VMA) are extremely sensitive and specific tumor markers and are used in diagnosis, treatment response assessment and post-treatment surveillance. The largest national treatment groups from North America, Europe and Japan have formed the International Neuroblastoma Risk Group Task Force (INRG) to identify prognostic factors, to understand the mechanisms of tumorigenesis in this rare disease and to develop multi-modality therapies to improve outcomes and decrease treatment-related toxicities. This international cooperation has resulted in a significant leap in our understanding of the molecular pathogenesis of neuroblastoma. Lower staged disease can be cured if the lesion is resectable. Treatment of unresectable disease (loco-regional and metastatic) is stratified depending on clinical features (age at presentation, staging investigations) and specific tumor biological markers that include histopathological analyses, chromosomal abnormalities and the quantification of expression of an oncogene (MYCN). Modern treatment of high-risk neuroblastoma is the paradigm for the evolution of therapy in pediatric oncology. Outcomes have improved substantially with multi-modality therapy, including chemotherapy, surgery, radiation therapy, myeloablative therapy with stem cell transplant, immunotherapy and differentiation therapy; these comprise the standard of care worldwide. In addition, newer targeted therapies are being tested in phase I/II trials. If successful these agents will be incorporated into mainstream treatment programs.
登录
查看更多内容
婴儿肌纤维瘤病中碘 131 间碘苄胍的摄取。
影响因子：
10.6
作者：
Stewart,RE;Grossman,DM;Shulkin,BL;Shapiro,B
通讯作者：
Shapiro,B
影响因子：
10.3
作者：
Asgharzadeh, Shahab;Pique-Regi, Roger;Seeger, Robert C.
通讯作者：
Seeger, Robert C.
影响因子：
10.5
作者：
Schlisio, Susanne;Kenchappa, Rajappa S.;Kaelin, William G., Jr.
通讯作者：
Kaelin, William G., Jr.
DOI：
--
发表时间：
1999
期刊：
The New England journal of medicine
影响因子：
--
作者：
K. Matthay;J. Villablanca;R. C. Seeger;D. Stram;R. E. Harris;N. Ramsay;P. Swift;H. Shimada;C. T. Black;G. M. Brodeur;R. Gerbing;C. P. Reynolds
通讯作者：
K. Matthay;J. Villablanca;R. C. Seeger;D. Stram;R. E. Harris;N. Ramsay;P. Swift;H. Shimada;C. T. Black;G. M. Brodeur;R. Gerbing;C. P. Reynolds
碘-131-间碘苄基胍联合清髓性化疗和自体干细胞支持治疗神经母细胞瘤的初步研究。
DOI：
10.1200/jco.2002.08.124
发表时间：
2002
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Yanik,GregoryA;Levine,JohnE;Matthay,KatherineK;Sisson,JamesC;Shulkin,BarryL;Shapiro,Brahm;Hubers,David;Spalding,Susan;Braun,Tom;Ferrara,JamesLM;Hutchinson,RaymondJ
通讯作者：
Hutchinson,RaymondJ